Table 1.
Baseline patient characteristics
| Parameter | Group A = with tafamidis | n | Group B = without tafamidis | n | p value |
|---|---|---|---|---|---|
| Age (years) | 76 (73–81) | 20 | 80 (75–82) | 20 | 0.18 |
| Males/females | 18/2 | 20 | 15/5 | 20 | 0.43 |
| BMI (kg/m2) | 25 (24–28) | 20 | 25 (23–29) | 20 | 0.90 |
| eGFR (CKD-EPI) (mL/min/1.73 m2) | 58 (47–67) | 20 | 60 (54–68) | 20 | 0.61 |
| NYHA class | 3 (2.0–3.0) | 20 | 2.0 (1.3–2.0) | 20 | 0.006 |
| NT-proBNP (pg/ml) | 2068 (1646–3267) | 16 | 1810 (1260–2858) | 16 | 0.19 |
| NAC (National Amyloidosis Centre) Staging Score | |||||
| Stage I | 12 | 20 | 16 | 20 | 0.31 |
| Stage II | 5 | 2 | |||
| Stage III | 3 | 2 | |||
| Medication | |||||
| ß-blockers | No. of patients | (No.) | No. of patients | (No.) | |
| Metoprolol | 4 | 3 | 8 | 4 | 0.69 |
| Bisoprolol | 9 | 6 | |||
| Carvedilol | 1 | 0 | |||
| Nebivolol | 0 | 1 | |||
| Diuretics | No. of patients | (No.) | No. of patients | (No.) | |
| Loop diuretics | 13 | 7 | 11 | 6 | 0.74 |
| Thiazides and thiazide-like | 3 | 1 | |||
| Potassium-sparing | 6 | 5 | |||
| Major CMR findings | |||||
| LV-EF (%) | 51 (48–58) | 19 | 57 (50–61) | 20 | 0.14 |
| LV-EDVi (ml/m2) | 91 (76–102) | 19 | 81 (77–98) | 20 | 0.90 |
| LV mass index (g/m2) | 104 (90–120) | 20 | 90 (82–104) | 20 | 0.046 |
| Max. LV thickness (mm) | 20 (18–22) | 20 | 20 (17–21) | 20 | 0.29 |
| RV-EF (%) | 49 (44–52) | 20 | 54 (46–61) | 20 | 0.17 |
| RV-EDVi (ml/m2) | 91 (75–101) | 20 | 80 (73–102) | 20 | 0.74 |
| 3D global longitudinal peak strain (%) | – 7.30 (– 7.70 to – 5.00) | 18 | – 8.60 (– 9.33 to – 7.45) | 20 | 0.012 |
| Apical/(basal + mid) strain ratio (3D), n | 0.81 (0.79–1.11) | 18 | 0.83 (0.67–0.90) | 20 | 0.19 |
| Global native T1 [950–1050 ms] | 1111 (1094–1125) | 17 | 1097 (1077–1126) | 17 | 0.33 |
| Basal septal native T1 [950–1050 ms] | 1110 (1101–1127) | 17 | 1096 (1049–1128) | 17 | 0.43 |
| Global ECV [25–31%] | 57 (51–62) | 17 | 56 (48–60) | 17 | 0.51 |
| Septal ECV [25–31%] | 64 (52–70) | 17 | 57 (48–66) | 17 | 0.15 |
All data are given as median (interquartile range), if not mentioned otherwise. Units are mentioned in small brackets (). Normal range of values are mentioned in large brackets []
BMI body mass index, eGFR (CKD-EPI) estimated glomerular filtration rate according – chronic kidney disease epidemiology collaboration, NYHA New York Heart Association, NT-proBNP N-terminal pro brain natriuretic peptides, CMR cardiovascular magnetic resonance, LV left ventricle, RV right ventricle, EF ejection fraction, EDVi enddiastolic volume index, ECV extracellular volume fraction
p < 0.05 is considered as significant